No Data
No Data
Express News | Cailong Pharmaceutical: The subsidiary obtained marketing approval for lysapirine as a chemical raw material
Sailong Pharmaceutical (002898.SZ): 2023 net profit of 9.533,700 yuan, plans to distribute 10 to 0.2 yuan
Gelonghui, April 19 | Sailong Pharmaceutical (002898.SZ) announced its 2023 annual report. Operating income for the reporting period was 311 million yuan, up 17.58% year on year; net profit attributable to shareholders of listed companies was 9.537 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 2,4359 million; basic income per share was 0.0542 yuan; it plans to distribute a cash dividend of 0.20 yuan (tax included) to all shareholders for every 10 shares.
Sailong Pharmaceutical (002898.SZ) reported 2023 annual results, with a net profit of 9.53337 million yuan, turning a year-on-year loss into a profit
Sailong Pharmaceutical (002898.SZ) released its 2023 annual report. The company achieved operating income of 3 during the reporting period...
A-share innovative drug concept stocks fell, and Osecon fell more than 4%
Gelonghui, March 18 | Osecon fell more than 4%, Sailong Pharmaceutical and Baiyunshan fell more than 3%, and Luoxin Pharmaceutical and Pharmaceutical Kangde followed suit.
A-share innovative pharmaceutical stocks collectively opened higher, and many stocks such as Zhaoyan New Pharmaceutical rose and stopped
Gelonghui, March 14 | Zhaoyan Pharmaceutical, Sailong Pharmaceutical, and Luoxin Pharmaceutical rose and stopped; Zhongsheng Pharmaceutical, Hengrui Pharmaceutical, and Hisco are close to rising or stopping. Eddy Pharmaceuticals, Betta Pharmaceuticals, Biotech, Junshi Biotech, and Colon Pharmaceuticals all strengthened collectively. According to the news, a document on the “Implementation Plan for Supporting the Development of Innovative Drugs in the Whole Chain (Draft for Comments)” was distributed online, which was interpreted by the market as a major benefit for the innovative drug industry.
Sailong Pharma's Unit Gets Nod to Market Pregabalin
Sailong Pharmaceutical Group's (SHE:002898) unit, Hunan Sailon Pharmaceutical, received the approval of China's National Medical Products Administration to market the raw drug ingredient pregabalin, a
No Data